Also trades as: GLAND.BO (BSE) · $vol 6M
GLAND.NS NSE
Gland Pharma Limited
1W: -0.8%
1M: -0.0%
3M: +16.7%
YTD: +52.5%
1Y: +45.5%
3Y: +86.6%
5Y: -25.8%
₹2,895.10 ($30.07)
+20.70 (+0.72%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$125.1B
+11.5% ▲
5Y CAGR: +14.0%
Total Liabilities
$21.5B
+3.8% ▲
5Y CAGR: +29.4%
Shareholders Equity
$103.6B
+13.2% ▲
5Y CAGR: +11.9%
Cash & Investments
$34.3B
+16.3% ▲
5Y CAGR: +2.7%
Total Debt
$2.8B
-9.6% ▼
5Y CAGR: +124.3%
Net Debt
-$30.8B
-37.1% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $3.2B | $19.1B | $3.6B | $25.6B | $33.6B |
| Short-Term Investments | $29.3B | $18.5B | $15.8B | $4.0B | $737M |
| Cash & ST Investments | $32.4B | $37.6B | $19.4B | $29.5B | $34.3B |
| Net Receivables | $12.9B | $10.4B | $16.5B | $15.2B | $18.9B |
| Inventory | $12.3B | $19.8B | $16.8B | $16.9B | $17.4B |
| Other Current Assets | $733M | $1.1B | $3.4B | $6.3B | $4.6B |
| Total Current Assets | $58.5B | $69.0B | $56.5B | $67.8B | $75.3B |
| Property, Plant & Equip. | $17.3B | $17.4B | $38.7B | $39.4B | $44.3B |
| Goodwill & Intangibles | $125M | $117M | $3.5B | $3.5B | $4.0B |
| Long-Term Investments | $2.0B | -$734M | -$9.3B | $0 | $0 |
| Other Non-Current Assets | $814M | $1.1B | $16.7B | $921M | $872M |
| Total Non-Current Assets | $19.8B | $18.8B | $50.2B | $44.4B | $49.8B |
| Total Assets | $78.3B | $87.8B | $106.6B | $112.2B | $125.1B |
| — Liabilities — | |||||
| Accounts Payable | $4.6B | $5.9B | $8.6B | $8.2B | $8.3B |
| Short-Term Debt | $1M | $6M | $2.1B | $1.9B | $1.7B |
| Deferred Revenue | $339M | $760M | $854M | $0 | $0 |
| Other Current Liabilities | $422M | $163M | $808M | $5.4B | $5.2B |
| Total Current Liabilities | $5.8B | $7.3B | $14.0B | $15.6B | $16.1B |
| Long-Term Debt | $38M | $33M | $1.1B | $777M | $699M |
| Other Non-Current Liab. | $17M | $17M | $1.4B | $1.5B | $2.4B |
| Total Non-Current Liabilities | $940M | $897M | $5.4B | $5.1B | $5.4B |
| Total Liabilities | $6.8B | $8.2B | $19.4B | $20.7B | $21.5B |
| — Equity — | |||||
| Common Stock | $164M | $165M | $165M | $165M | $165M |
| Retained Earnings | $52.3B | $60.2B | $67.9B | $71.6B | $0 |
| Accumulated OCI | $115M | -$16M | -$97M | $412M | $0 |
| Total Stockholders Equity | $71.6B | $79.6B | $87.2B | $91.5B | $103.6B |
| Total Liabilities & Equity | $78.3B | $87.8B | $106.6B | $112.2B | $125.1B |
| — Key Metrics — | |||||
| Total Debt | $47M | $45M | $3.7B | $3.1B | $2.8B |
| Net Debt | -$3.1B | -$19.0B | $151M | -$22.4B | -$30.8B |
| Total Investments | $31.3B | $17.8B | $6.6B | $4.0B | $737M |